Novartis Pharmaceuticals
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Conditions: Acromegaly
The present study is planned as an expanded treatment protocol to provide acromegalicpatients for whom medical therapy is appropriate access to pasireotide LAR whileregulatory approval for pasireotide is sought.
Novartis
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Conditions: Neoplasms, Breast
This study will provide pre-approval drug access to lapatinib, in combination withcapecitabine, to patients whose breast cancer had progressed on other therapies
Neuraptive Therapeutics Inc.
NTX-001 to Repair Peripheral Nerve Transection(s)
Conditions: Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves
The proposed use of NTX-001 for transections of upper extremity and facial peripheralnerves, acutely or planned.
Matrix Biomed, Inc.
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Conditions: Metastatic Cancer
The objective is to provide terminally diagnosed patients with a last line of treatmentwhile improving overall quality of life. Tempol can be added to any chemotherapy regimento potentially reduce side effects and overcome chemoresistance.
W.L.Gore & Associates
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE)
Conditions: Thoracoabdominal Aneurysm
Expanded access tothe GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis is safe andeffective in the treatment of thoracoabdominal and pararenal aneurysms.
DBV Technologies
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
Conditions: Peanut Allergy
This is an open label expanded access program for male and female patients 2 years orolder, to provide continued desensitization treatment with DBV712 250 mcg.
AstraZeneca
Himalaya Early Access Program
Conditions: Unresectable Hepatocellular Carcinoma
To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IVadministered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab1500 mg IV Q4W monotherapy in patients with unresectable HCC.
Ionis Pharmaceuticals, Inc.
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Conditions: Familial Chylomicronemia Syndrome
The purpose of the Expanded Access Program is to provide pre-approval access of olezarsento eligible patients with Familial Chylomicronemia Syndrome (FCS).